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Summary
Levodopa (LD) has been the first choice in the management of Parkinson’s disease 
(PD), since its introduction in the drug market; however, its prolonged use is related to 
the occurrence of motor complications, affecting the functionality and quality of life. 
Parkinson’s disease is one of the most frequent among the neurodegenerative diseases 
in the world, and it is expected that the number of people who suffer it, will increase 
due to global population aging. The PD represents, nowadays and for the future, a 
high economic burden from all perspectives, including patients, payers, and society. 
So it is necessary to know about the use of LD in its treatment and to realize the 
quality of pharmacoeconomic studies in the past five years, to identify reliable sources 
of information related to the costs and benefits of this medication to contribute in 
making decisions. The aim of this paper is to assess the methodological quality of 
pharmacoeconomic studies related to the use of LD in PD, specifically those that are 
identified as cost-utility studies, applying the QHES instrument. A total of 19 articles 
were found, of which 5 met the inclusion criteria and were subjected to examination. 
The average overall score obtained after the evaluation was 77.2 out of 100, making 
evident a good quality of studies according to the method used.
Keywords: Levodopa, Parkinson’s disease, cost-utility, methodological quality, QHES 
(Quality of Health Economic Studies).
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Resumen
Evaluación de la calidad de estudios farmacoeconómicos  
del uso de Levodopa para el manejo de la enfermedad  
de Parkinson, 2010-2015 
La Levodopa (LD) ha sido desde su introducción en el mercado la primera elección 
en el manejo de la enfermedad de Parkinson (EP); sin embargo, su uso prolongado 
está relacionado con la aparición de complicaciones motoras, afectándose la funcio-
nalidad y calidad de vida. La EP es una de las enfermedades neurodegenerativas que 
se presenta con mayor frecuencia en el mundo y se espera que el número de personas 
que la padecen aumente, debido al envejecimiento poblacional a nivel mundial. La 
EP representa, actualmente y a futuro, una alta carga económica desde todas las 
perspectivas, incluyendo: pacientes, pagadores y la sociedad; por lo cual es necesario 
conocer el uso de la LD en el tratamiento de la misma y lograr determinar la calidad 
de los estudios farmacoeconómicos realizados en los últimos cinco años, para iden-
tificar fuentes fiables de información relacionadas con los costos y los beneficios de 
este medicamento que aporten en la toma de decisiones. El objetivo de este artículo 
es evaluar la calidad metodológica de los estudios farmacoeconómicos relacionados 
con el uso de la LD en la EP, específicamente aquellos que se cataloguen como estu-
dios de costo-utilidad, aplicando el instrumento QHES. Se encontraron en total 19 
artículos, de los cuales cinco cumplieron los criterios de inclusión y fueron sometidos 
al respectivo análisis. El puntaje global promedio obtenido posterior a la evalua-
ción fue de 77,2 sobre 100, haciendo evidente una buena calidad de los estudios de 
acuerdo con el método utilizado.
Palabras clave: Levodopa, enfermedad de Parkinson, costo-utilidad, calidad metodo-
lógica, QHES (Quality of Health Economic Studies).
Introduction
Since the Parkison’s disease attributes were outlined in 1817 by English surgeon James 
Parkinson, there have been advanced to pinpoint what PD exactly is. Today, it is known 
that the Parkinson’s disease is a neurodegenerative pathology, which attributes are tremors, 
hypokinesia, rigidity, and postural changes. Moreover, with the technology advance-
ments, the PD’s neurophysiological deficit is due to an affectation in the dopaminergic 
neurogenesis without a fully elucidated etiology [1, 2].
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Since 1960’s, Levodopa (LD) is part of the PD’s treatment, and it is still a standard drug 
in the therapeutic arsenal for the disease’s management [3-7]. Besides, it satisfies two of 
the most relevant aspect when assessing an anti-Parkinson’s medication effectiveness, 
disability, and mortality. And despite LD’s known side effects, its frequent use has not 
diminished considering the lack of achievement expected of the new medicines [8].
It is estimated that PD’s prevalence will double for the year 2050; moreover, the adverse 
effects of anti-Parkinson’s medications will increase in a similar proportion. For this rea-
sons, strategies have been designed to enhance the availability in the cerebral level and 
to increase the medication’s plasma half-life with the passage of the years; for instance, 
sustained action LD was created, and it was associated with inhibitors of catechol-
O-methyltransferase (COMT), like Entacapone and Tolcapone. Another strategy is 
the alternative dosage forms that have been employed for PD advanced patients, for 
example, it is used the continuous intraduodenal infusion method to maintain drug 
stable concentrations, thus, reducing the fluctuations [9, 10].
Typically, PD studies have been focused on motor aspects; nevertheless, as new prob-
lematics are addressed, other pathologic aspects became relevant, like depression, cog-
nitive deterioration, and behavior disorders. Other factors stir interest, for instance, a 
patient can be developed dementia in the PD’s natural course, and how it affects the 
caregivers, who developed negative emotions and significant stress as result of caring 
for a chronically-ill person [11, 12].
In Colombia, it is not possible to make a specific estimation of the PD’s future in a local 
level because of the lack of recent epidemiologic data. The most recent is from the mid-
nineties, EPINEURO, a neuro-epidemiologic baseline study, reported a prevalence of 
4.7 (IC95%: 2.2 to 8.9) [13]. 
Accordingly, it is necessary to identify the use of LP in the PD’s treatment and to deter-
mine the pharmacoeconomic studies’ quality that has been done in the last five years. 
In the literature exists multiple systematic reviews of Parkinson’s disease and others 
associated with the disease treatment [14-21]. But, there are not quality evaluations 
of the publication’s methodology focused on cost-utility studies of the LD used in the 
EP treatment.
The importance of conducting this kind of assessments is based on the fact that health 
care decisions and their subsequent resource distribution are taken, in many cases, based 
on the available literature as reference. The objective of this paper is to assess the meth-
odological quality of the pharmacoeconomic studies related to the Levodopa use in Par-
kinson’s disease treatment. Particularly, those studies catalog as a cost-utility study. Being 
the last one, the author’s preference for that kind of study relates the natural course of 
the disease with its effects on the life quality of both the patients and caregivers.




A bibliographic search was done in the following Databases: EMBASE, LILACS, 
and MEDLINE. The same MeSH terms were used in them: Parkinson Disease [Mesh] 
AND Cost-Benefit Analysis [Mesh] AND Levodopa [Mesh]. Four reviewers identified 
independently the eligible articles, which were selected by a consensus.
Inclusion and exclusion criteria
Internationally indexed articles were selected that comply with the following param-
eters: Adult population over eighteen years old, main diagnosis of Parkinson’s disease, 
cost-utility analysis (CUA), Levodopa is included among one of the comparators, it 
must be in English or Spanish, and it was published in the period from January 1st, 
2010 to December 1st, 2015.
Quality assessment
The QHES (Quality of Health Economic Studies) instrument was implemented to eval-
uate the selected articles [22]. 16 criteria were established in the instrument, which 
determined the three types of health care economic analysis: minimizing costs, cost-
effectiveness, cost-utility; as shown in Table 1.      
The four researchers read independently and then categorize each article according to 
the 16 items of the instrument. Subsequently, criteria were unified in the points where 
a disagreement in the rating was evidenced.
Data mining
In the review of each one of the articles, the extracted data was relevant for the analy-
sis of the evidence as comparators, perspective, measuring instrument of life quality, 
QALY, time horizon, cost per QALY gained, country, among others.
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Table 1. QHES (Quality of Health Economic Studies) Instrument [22].
Question Points Yes No
1 Was the article’s objective presented in a clear, specific, and measurable form? 7
2 Are the analysis’ perspectives mentioned (social, third-party payer, etc.) and the reason for its selection? 4
3
Were the estimates of the variables used in the analysis taken from the 
best available evidence (meaning, randomized clinical trial: the best, 
the experts’ opinion, the worst)?
8
4 If the estimates come from a subgroup analysis, were they predefined at the start of the study? 1
5 Was the uncertainty handled by 1) statistical analysis to deal with random events or by 2) sensitivity analysis to cover some assumptions? 9
6 Was the incremental analysis conducted between the alternatives for resources and costs? 6
7 Was the methodology for data mining (including the value of health states and other benefits) mentioned? 5
8
Does analysis horizon give time to the occurrence of all relevant and 
important results? Were costs and benefits beyond one year discounted 
(from 3% to 5%) and the discount rate justified?
7
9 Was the measurement of costs appropriate and the methodology for estimating quantities and unit cost described clearly? 8
10
Was the measurement(s) of primary results for the economic evaluation 




Were the measures of health/scales outcomes valid and reliable?
If previously approved measures of validity and reliability were 
unavailable, Was a justification given for the measure/scales used?
7
12
Were the economic model (including the structure), the analysis and 
methods of the study, and the numerator and denominator components 
presented in a clear and transparent manner?
8
13 Was the selection of the economic model, the main assumptions, and 
study’s limitations declared and justified? 7
14 Did the author(s) explicitly discuss the direction and the magnitude of potential biases? 6
15 Were the study’s conclusions/recommendations justified and based on the results of the study? 8
16 Was there a statement that would reveal the study funding source? 3
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Results and discussion
Due to the implications in the life quality of those with Parkinson’s disease (PD), only 
the cost-utility study was selected, which was subjected to the inclusion and exclusion 
criteria. In total 19 articles were found [23-41], of which 5 met the inclusion criteria 
and were submitted to the respective analysis (Figure 1). The list of excluded studies is 
provided in Annex (1).
Number of identied references by searching in
electronic database
n = 33
Number of identied aftere removing duplicates
n = 19
Number of ifull text articules assessed of eligibility
n = 5





Figure 1. Flowchart for the evidence selection.
In all the cases, Levodopa was found as a comparator, regardless of whether it was 
concomitantly administered with another therapy. Two of the studies have a social 
perspective; three studies include a third-party payer perspective, and only one has a 
health professionals perspective; clarifying that one of the studies was carried out from 
two perspectives. It should be noted that four of the five studies included a Markov 
model, thus simulating in a more ‘realistic’ way what occurs in the disease process. The 
articles belonged to the following countries: two from the United Kingdom, one from 
the United States, one from Netherlands, and one from Norway (Table 2).
262
Nelson H. Hermida Gutiérrez, Lina M. Sanabria Becerra, Jorge A. Díaz Rojas
Table 2. Characteristics of the cost-utility studies. 
Study Objective Perspective Country
Study 
Considerations
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Table 2. Characteristics of the cost-utility studies (continuation).
Study Objective Perspective Country
Study 
Considerations
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advance motor 
fluctuations 







Markov model of 
2 years
















care for patients 
with advanced 
Parkinson’s 

















*RCT: Randomized clinical trial. **PDQ (Parkinson’s Disease Quality of Life Questionnaire). ***PD: Parkinson’s disease.
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Only two articles have a time horizon of fewer than two years; in both of them, the 
discount rate was not taken into account, in one of them because the time horizon was 
less than one year. As a relevant finding, all the studies stated the resources origins that 
financed the investigation, the great majority done by the pharmaceutical industry. 
When evaluating the quality of pharmacoeconomic studies with the QHES (Quality 
of Health Economic Studies) instrument, it was found that all the studies reached an 
average score higher than 60, which reveals a good quality in the studies submitted to 
the qualification (Table 3). The overall detailed analysis of Table 3 allowed to make the 
following observations: 
1. The criteria 1, 2, 5, 6, 7, 13, and 16 were fully satisfied by all the articles. Those referred 
to the following considerations: the goal and methodology of the study’s data mining 
were explicit, the analysis perspectives were always mentioned, an incremental analysis 
and the study model, as well as, the source of funding was always declared; moreover, a 
sensibility analysis was conducted in all the cases. For these results, a good quality can be 
partially attributed to the evaluated studies.
2. The estimation of used variables was described except in one article. In two articles, 
the discount rate was not explicitly given, and in another, the cost measurements were 
not fully described, the primary outcome measures were only specified in one article, 
and in only two cases, the measures of outcome were valid and reliable. In two articles, 
it did not discuss the magnitude of the potential biases and the conclusions were not 
clear concerning the model results.
Cost-utility study
Eggington et al. [23], compared the deep cerebral stimulation combine with the best 
medical treatment as a management option for Parkinson’s disease versus the best 
medical treatment independently (Levodopa and other antiparkinsonians) from a 
third -party perspective. Data of deep cerebral stimulation effects in the progressing 
PD symptoms from 6-months randomized clinical trial (RCD) were used to develop a 
Markov model, using a time horizon of 5 years. The total costs were: € 51,499 for deep 
brain stimulation combined with the best medical treatment, and € 36,023 for the 
best medical treatment independently (Levodopa and other antiparkinsonians), with 
QALYs of 2.21 and 1.21 respectively giving an incremental cost-effectiveness relation 
of € 15,440 per QALY gained.
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Table 3. Quality evaluation of studies.
Criteria Eggington et al. [23]
Lundqvist 
et al. [24]






1 + + + + +
2 + + + + +
3 + - + + +
4 - - + - +
5 + + + + +
6 + + + + +
7 + + + + +
8 + - + - +
9 - + + + +
10 - - - - +
11 + + - - -
12 + + - + +
13 + + + + +
14 + + - - +
15 + + - - +
16 + + + + +
TOTAL 85 78 65 65 93
+ Criteria found in the study.  
- Article did not fulfill or partially fulfilled the criteria.
In the United Kingdom under the perspective used, the results suggest that deep 
brain stimulation is a cost-effective intervention in patients with advanced Parkinson’s 
disease who are eligible for surgery. However, this information should be taken with 
caution in the Colombian context, due to the marked differences between the popula-
tion and the health system of both countries. It is clarified that the costs reported and 
extracted from the articles were adjusted to the constant prices of October 2015 and 
were homogenized to a single currency (Euros), considering each country’s consumer 
price index (CPI) and the publication date of each article.
Lowin et al. [27] is another study conducted in the United Kingdom, in which the intes-
tinal gel of Levodopa/Carbidopa was evaluated, compared with the defined standard 
266
Nelson H. Hermida Gutiérrez, Lina M. Sanabria Becerra, Jorge A. Díaz Rojas
care as the best available oral medicine as medically determined in patients with 
advanced Parkinson’s disease. A Markov model was used to quantify costs and results, 
with a lifetime horizon. An incremental cost per AVAC of € 29,048 was obtained for 
the intestinal gel of Levodopa/Carbidopa compared to standard care. The results were 
sensitive at the time of the treatment, health status at the start of treatment, and long-
term benefit estimates. In this context, the intestinal Levodopa/Carbidopa gel is con-
sidered an effective treatment that improves the quality of life in advanced PD and 
should not be ignored despite the high cost involved, suggesting that this alternative 
could be considered cost-effective compared to standard care when other options of 
treatment are ineffective or inadequate. However, it is emphasized that more research 
is needed to fill gaps in information regarding the current data and to increase the 
robustness of the model.
In Norway, Lundqvist et al. [24] performed the study of a cohort of ten patients with 
advanced PD, who from an ineffective conventional (oral) treatment with LD switched 
to a new form of continuous intraduodenal administration of Levodopa (IDL). They 
had a follow-up of 12 months, used the unified scale of the PD to measure function 
and the questionnaire 15D for the quality of life. The objective of the study was to 
determine the costs and health consequences of the change from a conventional treat-
ment to IDL; all from a social perspective. Although the data on effectiveness, safety, 
and quality of life results were proprietary, they mention the various limitations from 
a methodological point of view and conclude that the change in this type of therapy 
in patients with advanced disease is not cost-effective in their country due to an addi-
tional cost of € 88,166,638 per QALY gained.
In the study by Van Boven et al. [25], the profitability of ropinirole prolonged release 
in Parkinson’s disease versus ropinirole immediate release, when used as a complement 
to Levodopa, was estimated. A Markov model was developed that included the fol-
lowing aspects related to the treatment: (I) the rate of progression of the disease, (II) 
rates of dyskinesia, and (III) adherence to medication. The base case analysis showed a 
favorable pharmacoeconomic profile for ropinirole prolonged release versus ropinirole 
immediate release. Overall, cost savings combined with moderate gains in life quality 
are considered and profitability remained acceptable within the investigated limits. In 
this study, it is concluded that ropinirole prolonged release presents a high probabil-
ity of cost savings or at least being considered cost-effective in the Netherlands when 
compared to ropinirole immediate release when used as a complement to Levodopa. It 
should be clarified that the article mentions how the cost per QALY can be calculated 
and the necessary data to do it; however, it does not present the punctual value, which 
was calculated by the researchers of this evaluation, obtaining a value of € 113600.
Pharmacoeconomic studies of Levodopa use in Parkinson’s diseases 
267
A study conducted in the United States by Groenendaal et al. [26] aimed to evaluate the 
cost-utility of rasagiline or Entacapone as an adjuvant to Levodopa versus Levodopa/
Carbidopa/Entacapone (LCE) and also in comparison to standard monotherapy with 
Levodopa in patients with advanced PE and motor fluctuations in that country. The 
study was carried out under two perspectives, from the perspective of society and from 
the perspective of the third payer, using a Markov model in which they performed six 
cycles of four months for a two-year time horizon with three health states and using 
the odds of varying from one health condition to another as reported in controlled 
clinical trials. The results show a higher cost-effectiveness in the use of rasagiline plus 
Levodopa, with cost-per-QALY data earned € -15,905 and Levodopa-Carbidopa-
Entacapone-€ 17,051, when assessed from the perspective of the third-party payer. 
Moreover, better results are gained with the alternative of Entacapone plus Levodopa 
(cost per QALY gained € -14,560), assessed from the social perspective.
In all of the articles evaluated, the cost of QALYs gained was recalculated, which is 
presented underlined in Table 4, to compare it with the value reported by the authors. 
In all cases, there were minor differences; nonetheless, in the analysis performed by Van 
Boven et al. [25] as mentioned above, a punctual value was not presented.
Table 4. Results of the Cost-Utility Studies.
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Table 4. Results of the Cost-Utility Studies (continuation).
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* Costs reported and extracted from the articles were adjusted to constant prices of October 2015 and were homogenized 
to a single currency (Euros); considering each country’s consumer price index (CPI) and the publication date of each article.
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Strength and limitations
The assignment of resources for health is limited in the case of the Colombian system. 
It is not based solely on economic considerations; it requires the opinion of experts 
and the review of economic analyses. Therefore, a quality analysis of information such 
as the one carried out in this research is relevant, especially for a disease, such as, Par-
kinson’s disease whose prevalence is expected to increase over the years, and the deci-
sions taken should take into account the improvement in the life quality of the patient 
along with the reduction of social burden.  
Regarding the evaluation of the studies with the QHES (Quality of Health Economic 
Studies) instrument, a good quality was generally found because an average score of 
more than 60 was always obtained. This can be correlated with the detailed description 
in each article of aspects such as the objective, data mining methodology, analysis per-
spective, study model, the source of funding, and sensitivity analysis. Regarding applica-
bility, it is important to note that the interventions, the comparator, and the country in 
which each study was performed, since, the costs reported were clearly described, and in 
all cases, the study population was appropriate for the subject evaluated [42, 43].
It is appropriate to mention the multiple methodological limitations of pharmacoeco-
nomic assessments: results are obtained from assumptions that are supported by prob-
abilities, sensitivity analyses do not necessarily have the capacity to reflect the reality of 
population behavior nor the different scenarios that arise in the course of the diseases, 
particularly those of neurological origin. Likewise, the external validity of these articles 
is low due to the reduced possibility that the results can be extrapolated to different 
regions from a social, cultural, and economic point of view. Authors such as Welte et 
al. [44] propose transfer criteria to evaluate, such as perspective, discount rate, cost 
approach, health system characteristic, variability in clinical practice, availability of 
technology, epidemiological variables of Illness, life expectancy, preferences for socio-
economic status, productivity, and lost work time, among others. 
It is necessary to determine in each case: the correspondence between the country of 
study and the country of decision, the degree to which the criterion is relevant to the 
technology investigated and the likely effect of the transfer criterion on the results 
[43], evidencing this is the need to carry out studies that evaluate the life quality in 
PE and the costs from different perspectives in Latin America, so as to allow adequate 
decision making based on methodologically structured studies.
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Conclusions
In this study, a review of the pharmacoeconomic evaluations for the use of Levodopa in 
Parkinson’s disease was carried out, based on the QHES instrument [22], which quali-
fies methodological quality and has been used by other authors previously [45-49].Only 
the articles that met inclusion criteria and were considered of cost-utility were taken, 
finding that the five articles analyzed obtained an overall average score of 77.2 out of 
100. This reflects that these studies are of good quality, and this is probably attributable 
to the fact that they were recently carried out following the current guidelines.
Latin American articles were not found in the systematic search carried out. Therefore, 
it is necessary to conduct own studies that may be closer to our reality, taking into 
account the differences in the population, the resources destined for health, and the 
therapeutic alternatives employed.
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